Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 22

Results For "EBITDA"

354 News Found

SMS Pharmaceuticals reports robust Q2FY24 operational performance
News | November 10, 2023

SMS Pharmaceuticals reports robust Q2FY24 operational performance

Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore


GSK registers 5% revenue growth in Q2 FY24
News | November 10, 2023

GSK registers 5% revenue growth in Q2 FY24

General Medicine grows 5% and Vaccines 10% led by Shingrix


Bayer posts Q3 2023 Group sales Euro 10.34 billion
News | November 09, 2023

Bayer posts Q3 2023 Group sales Euro 10.34 billion

We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”


Biocon Biologics announces divestment of two non-core branded formulations
News | November 09, 2023

Biocon Biologics announces divestment of two non-core branded formulations

Total transaction value of the divestment is Rs. 3,660 million


Dr Reddy's Q2 FY24 PAT jumps 33% to Rs 1,480 Cr
News | October 30, 2023

Dr Reddy's Q2 FY24 PAT jumps 33% to Rs 1,480 Cr

Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter


Indian pharma industry to witness 8-10% revenue growth in fiscal 2024: CRISIL
News | September 12, 2023

Indian pharma industry to witness 8-10% revenue growth in fiscal 2024: CRISIL

Low-leveraged balance sheets, sizeable liquidity to keep credit profiles stable


Granules India posts Q1 FY24 revenue from operations at Rs. 985.5 Cr
News | August 10, 2023

Granules India posts Q1 FY24 revenue from operations at Rs. 985.5 Cr

API, PFI, and Finished dosages contribute 30%, 15%, and 55% of revenue from operations respectively for Q1FY24


Hikal posts Q1 FY 24 consolidated PAT at Rs. 6.92 Cr
News | August 09, 2023

Hikal posts Q1 FY 24 consolidated PAT at Rs. 6.92 Cr

US FDA approval is in line with de-risking strategy for additional API site to service our global customer base


Tatva Chintan Pharma Chem posts Q1 FY24 consolidated PAT at Rs. 9.50 Cr
News | August 06, 2023

Tatva Chintan Pharma Chem posts Q1 FY24 consolidated PAT at Rs. 9.50 Cr

The company has reported total income of Rs. 115.37 crores during the period ended June 30, 2023